Poly Medicure Ltd

Investor meetings

• Bandhan AMC one-on-one investor meeting on 27 August 2026, 03:40 PM, virtual.
• Sparx Capital meeting on 31 August 2026, 04:00 PM, at Registered Office, 232-B, Okhla, New Delhi.

Investor meeting schedule

• Bandhan AMC meeting: 27 August 2026 at 03:40 PM; virtual, one-on-one.
• Sparx Capital meeting: 31 August 2026 at 04:00 PM; registered office, New Delhi; one-on-one.
• No unpublished price sensitive information will be shared; subject to changes.

Investor meeting update

• One-on-one meeting with Wasatch Global on Aug 20, 2026 cancelled due to exigencies.

Investor meetings

• One-on-one meetings with Wasatch Global on Aug 20, 2026 (virtual).
• One-on-one meetings with Bajaj Alternative Investment Ltd. on Aug 20, 2026 (virtual).
• No unpublished price sensitive information will be shared during the meetings.

AGM Details

• Date/time/mode: 5 September 2026 at 11:00 IST, via VC/OAVM.
• Record closure: Register of Members closed 30 August to 5 September 2026 (inclusive).

Core Resolutions

• Adopt audited standalone financial statements for the year ended March 31, 2026.
• Adopt audited consolidated financial statements for the year ended March 31, 2026.
• Declare dividend of ₹3.50 per equity share for FY 2025-26.
• Re-appoint Rishi Baid as Director liable to retire by rotation.
• Re-appoint Devendra Raj Mehta as Non-Executive Non-Independent Director, aged 75.
• Approve remuneration to Cost Auditor Jai Prakash & Company for FY2027.

Dividend

• Dividend proposed: ₹3.50 per equity share.

Director Changes

• Rishi Baid to be re-appointed as Director liable to retire by rotation.
• Devendra Raj Mehta to continue as Non-Executive Non-Independent Director (age 75).

Cost Auditor Remuneration

• Remuneration approved for Cost Auditor: ₹1,10,000 plus taxes.

Book closure details

• Book closure from Aug 30, 2026 to Sep 5, 2026 (inclusive) for final dividend entitlement on FY2025-26.
• Record date: Aug 29, 2026, for determining dividend entitlement.
• AGM date: Sep 5, 2026.
• Dividend: ₹3.50 per equity share, subject to AGM approval.
• Security type: Equity shares.

AGM details

• 31st AGM to be held on 5 September 2026 at 11:00 AM IST via VC/OAVM.

Dividend proposal

• Board recommended final dividend of ₹3.50 per equity share (70%) for FY2025-26, subject to shareholder approval.

Regulatory updates for PAN/KYC

• SEBI circular requires physical shareholders to update PAN, KYC, and bank details with the RTA.

Dividend payout mechanics

• Dividends to be paid electronically; physical investors must update bank details.

Overview

• Main business: manufacturing, marketing, sale and distribution of medical devices.
• Reporting boundary: standalone BRSR for the year ended March 31, 2026.
• Exports account for about 65% of turnover.
• Markets span 100+ countries via a global distributor network.
• Standards and assurance: ISO 9001/13485/14001, MDSAP; TÜV SÜD partial BRSR Core assessment.

Key ESG Risks & Opportunities

• Product quality and safety risk; mitigated by ISO 13485 QMS, audits, and ongoing R&D.
• Ethics and compliance risk; ABAC policy, Code of Conduct, whistleblower mechanisms.
• Workforce health and safety risk; 100% OHS coverage; LTIFR employees 0, workers 1.04.
• Climate action opportunity; Net Zero by 2050; 9.9 MWp solar PPA; rooftop solar expansion.
• Sustainable sourcing and supply chain; 18.47% inputs from MSMEs; 45% inputs sustainable.
• Data privacy risk; robust privacy policy; data breaches reported as 0 in FY2026.

Governance & Policy Highlights

• Board oversight via CSR Committee; half-yearly review of NGRBCs.
• Policies: ABAC, Code of Conduct, Whistleblower, CSR, related-party transactions.
• Independent assurance for BRSR Core indicators; partial scope by TÜV SÜD.
• Public policy advocacy: engaged with policymakers; withdrawal of 14 QCOs around Nov 2025.
• No material penalties or enforcement actions reported in FY2025-26.

Social Responsibility & Workforce

• Total workforce: 1,553; 1,384 male and 169 female employees.
• Diversity target: 33% women in white-collar roles by 2035; current share 10.88%.
• Training: 100% coverage across BoD, KMP and employees; 55 programs.
• Well-being spend: INR 1.4417 crores; revenue ~INR 1,662.46 crores; 0.09% of revenue.
• LTIFR: employees 0; workers 1.04; four injuries; no fatalities.
• POSH complaints: 0; grievance mechanisms include whistleblower and HR channels.

Environmental Performance

• Total energy: 244,238.48 GJ; renewable energy: 20,573.52 GJ (8.42%).
• Non-renewable energy: 223,664.96 GJ.
• Scope 1 emissions: 3,762.39 tCO2e; Scope 2 emissions: 36,910.70 tCO2e.
• Waste: total 2,203.361 MT; recycled 2,022.07 MT; incinerated 124.57 MT.
• Water withdrawals: 90,170.52 kL; groundwater 3,473.95; third-party 82,996.1; other 3,700.469.
• Standards: ISO 9001/13485/14001; MDSAP; 9.9 MWp solar PPA; rooftop solar expansions.

Stakeholder Engagement & Complaints

• Key stakeholder groups include employees, shareholders, customers, suppliers, communities, and government.
• Engagement channels include meetings, surveys, investor calls, and CSR initiatives; materiality exercise informs priorities.
• Customer complaints: 2,249 filed in FY2025-26; 0 pending at year-end.
• Community grievances: 0; engagement via NGO partners and CSR programs.
• Grievance mechanisms: whistleblower policy and HR/supervisor channels with board oversight.

Other Notable Metrics

• Sustainable sourcing: 18.47% inputs from MSMEs; 45% inputs from sustainable sources.
• Wages and regional job creation: metropolitan areas dominate wage cost ~95%; small towns ~5%.
• Related-party transactions: purchases from related parties 0.93%; sales to related parties 2.80%.
• Investments in related parties: INR 50,329.74; total investments INR 124,574.1.
• Scope 3 emissions: 93,809.28 tCO2e; per-turnover intensity 0.00000564.
• Green credits: 0; assurance via TÜV SÜD for BRSR Core indicators.
• Public policy advocacy results include withdrawal of 14 QCOs (Nov 2025).